Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
PubMed
29572505
PubMed Central
PMC6087720
DOI
10.1038/s41375-018-0023-2
PII: 10.1038/s41375-018-0023-2
Knihovny.cz E-zdroje
- MeSH
- adenin analogy a deriváty MeSH
- lidé MeSH
- lymfom z plášťových buněk farmakoterapie patologie MeSH
- mezinárodní agentury MeSH
- míra přežití MeSH
- následné studie MeSH
- piperidiny MeSH
- prognóza MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- pyrazoly aplikace a dávkování MeSH
- pyrimidiny aplikace a dávkování MeSH
- sirolimus aplikace a dávkování analogy a deriváty MeSH
- záchranná terapie * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
- Názvy látek
- adenin MeSH
- ibrutinib MeSH Prohlížeč
- piperidiny MeSH
- pyrazoly MeSH
- pyrimidiny MeSH
- sirolimus MeSH
- temsirolimus MeSH Prohlížeč
1st Dept Medicine Charles University General Hospital Prague Czech Republic
APHP Saint Louis Hospital Hemato oncology Diderot University Paris France
Departement Oncologie UZ Gent Ghent Belgium
Department of Hematology Jagiellonian University Krakow Poland
Department of Medicine 3 Klinikum der Universität München LMU Munich Germany
Instituto Biosanitario de Salamanca Hospital Clinico Universitario Salamanca Salamanca Spain
Janssen Research and Development Leiden The Netherlands
Janssen Research and Development Raritan NJ USA
Klinikum der Ruprechts Karls Universität Heidelberg Med Klinik u Poliklinik 5 Heidelberg Germany
Plymouth University Medical School Plymouth UK
Seoul St Mary's Hospital Seocho gu Seoul South Korea
Zobrazit více v PubMed
Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:512–8. doi: 10.1200/JCO.2008.16.8435. PubMed DOI
IMBRUVICA® [US prescribing information]. Sunnyvale, CA: Pharmacyclics, LLC; Horsham, PA: Janssen Biotech, Inc.; 2017.
Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16. doi: 10.1056/NEJMoa1306220. PubMed DOI PMC
Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–iv71. doi: 10.1093/annonc/mdx223. PubMed DOI
Dreyling M, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international randomised, open-label, phase 3 study. Lancet. 2016;387:770–8. doi: 10.1016/S0140-6736(15)00667-4. PubMed DOI
Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–74. doi: 10.1200/JCO.2006.07.9665. PubMed DOI
Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–95. doi: 10.1200/JCO.2013.49.2835. PubMed DOI PMC
Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–9. doi: 10.1200/JCO.2008.20.7977. PubMed DOI
Jurczak W, Ramanathan S, Giri P, Romano A, Mocikova H, Clancy J et al. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. Leuk Lymphoma. 2018;59:670–8. PubMed
Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, et al. Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a phase II clinical trial. Blood. 2016;128:147. doi: 10.1182/blood-2016-05-716167. PubMed DOI
